Medplus Subsidiary Receives Suspension Orders for Drug Licenses in Karnataka and Andhra Pradesh
Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services Limited, has received three suspension orders pertaining to drug licenses for stores located in Karnataka and Andhra Pradesh. The suspensions were ordered by various drug control administrations.The actions taken resulted from alleged contraventions under Rule 65 of the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. These administrative orders involve varying durations of license suspension for multiple locations.
| Authority | Location & Action Details | Date of Order Receipt | Potential Revenue Loss |
|---|---|---|---|
| Assistant Director, Drugs Control Administration, Hubli Circle, Karnataka | Suspension of Drug License for one day of a store in Adarsha Nagar Hubli. | 25.06.2026 | Rs 0.22 lacs |
| Assistant Director, Drugs Control Administration, Gadag Circle, Karnataka | Suspension of Drug License for two days of a store located at Rani Road Gadag. | 25.06.2026 | Rs 0.60 lacs |
| Assistant Director, Drugs Control Administration, Serilingampally, Andhra Pradesh | Suspension of Drug License for three days of a store situated in Radhakrishna Nagar Attapur. | 25.06.2026 | Rs 0.76 lacs |
The suspensions relate to the drug licenses for stores across both states. The potential revenue losses identified due to these regulatory actions amount to combined figures noted in the table.
MEDPLUS Stock Price Movement
Shares of Medplus Health Services Limited slipped on Thursday, closing at ₹835 after shedding 0.35% from the previous close. The equity saw a decrease of ₹2.95 during the session amidst strong trading volume totaling 202,137 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.